Month: December 2023

Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Appoints Ann Merchant to the Board of Directors CARDIFF, United Kingdom, Dec. 29, 2023 (GLOBE NEWSWIRE) – Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs including Type 1 diabetes and rare / orphan brain cancers, is pleased to announce the appointment of Ann Merchant to the Board of Directors of the Company as Non-executive Director with effect from 31 December 2023. Since 2018, Ann Merchant has served as Vice President for MorphoSys, and currently as Head of Global Supply Chain and External Operations. Prior to joining MorphoSys, from September 2011 to August 2018, Ms. Merchant served as the President of Schreiner Medipharm. Between 1994...

Press release, Helsinki, 29 December 2023 at 10 AM (EEST) Nexstim Plc (NXTMH:HEX) (“Nexstim” or “Company”) has received an order for an NBS System 5 from a distributor company based in Europe. Nexstim’s NBS (Navigated Brain Stimulation) System 5 is CE marked and FDA approved for presurgical mapping of the speech and motor cortices of the brain. In addition to its motor and speech mapping features, this specific system also includes therapeutic capabilities that allow the system to be used for the treatment of major depression and chronic neuropathic pain. Mikko Karvinen, CEO of Nexstim, comments: “We are happy with the number of Nexstim systems that have been acquired by our network of distributor representatives this year. Our Nexstim NBS System 5 combines both diagnostic and therapeutic applications and has proven...

Rokiskio suris AB informs that the operational results of the Group of Rokiskio suris AB for the year 2024 will be announced as follows: April 8th        Annual audited Consolidated Financial Statements for year 2023August 30th    Consolidated six month financial accountability of the Group for the year 2024 Dalius Trumpa, CEOTel.:+370 458 55200

The net asset value (NAV) of EfTEN United Property Fund was 10.66 euros at the end of November, increasing by 0.4% over the month. If the fund’s investment in the of EfTEN Real Estate Fund AS shares is valued on the NAV basis, the NAV of EfTEN United Property Fund would have been 10.85 euros, increasing also by 0.4%. In December, in the Uus-Järveküla residential development, the first 6 terraced houses were handed over to clients (property right contracts were concluded). A total of 50 semi-detached houses have been sold from the first development stage. Most of those will be handed over to clients in January and February 2024. As part of the second stage, 16 semi-detached houses and 14 terraced houses will be built. Half of them have been booked by clients to date, and construction work is planned to start in the coming spring....

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Dec. 28, 2023 (GLOBE NEWSWIRE) — Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) announces that it intends to complete a non-brokered private placement financing (the “Private Placement”) of up to 3,750,000 units of the Company (“Units”) at a price of $0.40 per Unit for aggregate gross proceeds of up to $1,500,000. Each Unit shall consist of one common share in the capital of the Company (“Share”) and one (Share purchase warrant (“Warrant”), with each Warrant entitling the holder thereof to purchase a Share at an exercise price of $0.50 for a period of 24 months from the date of issuance. Closing of the Private Placement is anticipated to occur on or about January 12,...

VANCOUVER, British Columbia, Dec. 28, 2023 (GLOBE NEWSWIRE) — Alaska Energy Metals Corporation (TSX-V: AEMC, OTCQB: AKEMF) (“AEMC” or the “Company”) is pleased to announce it has closed a non-brokered private placement of flow-through common shares (“the financing”). The sole participant in the financing was Maple Leaf Funds through subscriptions by Maple Leaf Critical Minerals 2023-II Flow Through LP – Quebec Class and Maple Leaf Critical Minerals 2023 Super Flow Through LP – Quebec Class. “We are really pleased to have institutional investor Maple Leaf Funds as a shareholder of our company. This financing, done at a significant premium to our current market price, will allow us to advance the Angliers nickel project in Western Quebec” stated Company President & CEO Gregory Beischer. Two million shares were sold at a price...

TORONTO, Dec. 28, 2023 (GLOBE NEWSWIRE) — Immutable Holdings Inc. (NEO:HOLD; OTC: IHLDF) (“Immutable Holdings” or the “Corporation”), a publicly-traded blockchain holding company, is pleased to announce the voting results of its Annual General Meeting of Shareholders that was held on December 28, 2023 (the “Meeting”). Election of Directors Each of the nominees for election as directors listed in the Corporation’s management information circular dated November 13, 2023 (the “Circular”) were elected as directors of the Corporation for the ensuing year or until their successors are elected or appointed. Reappointment of Auditors At the Meeting, shareholders also approved the reappointment of Richter LLP as auditors of the Corporation for the ensuing year, as well as the authorization of the directors of the Corporation to fix the...

Action Retains Full Patient Access to MicroPulse® Transscleral Laser Treatment MOUNTAIN VIEW, Calif., Dec. 28, 2023 (GLOBE NEWSWIRE) — Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced all five Medicare Administrative Contractors (“MACs”) retired their local coverage determinations (“LCDs”) that were scheduled to take effect on January 29, 2024.   Iridex and other stakeholders opposing the LCDs have engaged with the MACs throughout the comment period to advocate for continued patient access to clinically proven safe and effective glaucoma treatments. The Company applauds the decision which effectively retains reimbursement and full access for Medicare patients...